<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01069289</url>
  </required_header>
  <id_info>
    <org_study_id>D589DC00007</org_study_id>
    <nct_id>NCT01069289</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of Symbicort® Turbuhaler® Versus Oxis® Turbuhaler® in Chronic Obstructive Pulmonary Disease (COPD) Patients</brief_title>
  <acronym>SUMIRE</acronym>
  <official_title>A Phase III, 12-week, Double-blind, Randomised, Parallel-group, Active-controlled, Multinational, Efficacy and Safety Study of Symbicort® Turbuhaler® 160/4.5 μg 2 Inhalations Twice Daily (Bid) Compared to Oxis® Turbuhaler® 4.5 μg 2 Inhalations Twice Daily (Bid) in Patients With Chronic Obstructive Pulmonary Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of the study is to investigate if Symbicort is more effective than Oxis
      in increasing forced expiratory volume in one second (FEV1), measured at the clinics, in
      patients with COPD.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pre-dose Forced Expiratory Volume in One Second (FEV1)</measure>
    <time_frame>Before randomization, 0, 4, 8 and 12 weeks after randomization</time_frame>
    <description>The ratio, expressed as percentage, of the geometric mean of available data for Weeks 0, 4, 8 and 12 to the baseline for each treatment group</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>1 Hour Post Dose Forced Expiratory Volume in One Second (FEV1)</measure>
    <time_frame>Before randomization, 0, 4, 8 and 12 weeks after randomization</time_frame>
    <description>The ratio, expressed as percentage, of the geometric mean of available data for Weeks 0, 4, 8 and 12 to the baseline for each treatment group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-dose Forced Vital Capacity (FVC)</measure>
    <time_frame>Before randomization, 0, 4, 8 and 12 weeks after randomization</time_frame>
    <description>The ratio, expressed as percentage, of the geometric mean of available data for Weeks 0, 4, 8 and 12 to the baseline for each treatment group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1 Hour Post-dose Forced Vital Capacity (FVC)</measure>
    <time_frame>Before randomization, 0, 4, 8 and 12 weeks after randomization</time_frame>
    <description>The ratio, expressed as percentage, of the geometric mean of available data for Weeks 0, 4, 8 and 12 to the baseline for each treatment group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Exacerbations</measure>
    <time_frame>Daily during 12-week randomization treatment</time_frame>
    <description>A Chronic Obstructive Pulmonary Disease (COPD) exacerbation was defined as worsening in COPD symptoms requiring treatment with either a course of systemic steroid or hospitalisation. The percentage of participants who had experienced COPD exacerbation at the end of the study for each treatment group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Chronic Obstructive Pulmonary Disease (COPD) Exacerbation</measure>
    <time_frame>Daily during 12-week randomization treatment</time_frame>
    <description>A Chronic Obstructive Pulmonary Disease (COPD) exacerbation was defined as worsening in COPD symptoms requiring treatment with either a course of systemic steroid or hospitalisation. Number of COPD exacerbation during 12-week randomization treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morning Peak Expiratory Flow(PEF)</measure>
    <time_frame>Daily during run-in period and daily during 12-week randomization treatment</time_frame>
    <description>The change from Run-in period average to Treatment period average for each treatment group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evening Peak Expiratory Flow (PEF)</measure>
    <time_frame>Daily during run-in period and daily during 12-week randomization treatment</time_frame>
    <description>The change from Run-in period average to Treatment period average for each treatment group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Number of Day With Exacerbation</measure>
    <time_frame>Daily during 12-week randomization treatment</time_frame>
    <description>Total number of days with COPD exacerbation for each treatment group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morning Forced Expiratory Volume in One Second (FEV1)</measure>
    <time_frame>Daily during run-in period and daily during 12-week randomization treatment</time_frame>
    <description>The change from Run-in period average to Treatment period average for each treatment group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evening Forced Expiratory Volume in One Second (FEV1)</measure>
    <time_frame>Daily during run-in period and daily during 12-week randomization treatment</time_frame>
    <description>The change from Run-in period average to Treatment period average for each treatment group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Night-time Awakening Due to Chronic Obstructive Pulmonary Disease (COPD) Symptoms</measure>
    <time_frame>Daily during run-in period and daily during 12-week randomization treatment</time_frame>
    <description>Scored 0 to 1 (0 = no awakening and 1 = awakening). The change from Run-in period average to Treatment period average for each treatment group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Breathlessness Due to Chronic Obstructive Pulmonary Disease (COPD) Symptoms</measure>
    <time_frame>Daily during run-in period and daily during 12-week randomization treatment</time_frame>
    <description>There are 5 alternatives (scored 0 to 4, with 4 being the most severe condition). The change from Run-in period average to Treatment period average for each treatment group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cough Due to Chronic Obstructive Pulmonary Disease (COPD) Symptoms</measure>
    <time_frame>Daily during run-in period and daily during 12-week randomization treatment</time_frame>
    <description>There are 5 alternatives (scored 0 to 4, with 4 being the most severe condition). The change from Run-in period average to Treatment period average for each treatment group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Chronic Obstructive Pulmonary Disease (COPD) Symptom Score</measure>
    <time_frame>Daily during run-in period and daily during 12-week randomization treatment</time_frame>
    <description>The Total COPD Symptom score is the sum of the measures night-time awakening, breathlessness and cough, ranges from 0 to 12 with 12 being the most severe. The change from Run-in period average to Treatment period average for each treatment group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of Rescue Medication</measure>
    <time_frame>Daily during run-in period and daily during 12-week randomization treatment</time_frame>
    <description>The change from Run-in period average to Treatment period average for each treatment group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>St George's Respiratory Questionnaire (SGRQ) Total Score</measure>
    <time_frame>Daily during run-in period and daily during 12-week randomization treatment</time_frame>
    <description>The change from Run-in period average to Treatment period average for each treatment group. The SGRQ ranges from 0 (no impairment of quality of life) to 100 (highest impairment of quality of life).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1293</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Symbicort Turbuhaler 160/4.5 microgram, 2 inhalations twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oxis Turbuhaler 4.5 microgram, 2 inhalations twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonide/formoterol (Symbicort Turbuhaler)</intervention_name>
    <description>2x160/4.5 microgram, inhalation, twice daily, 12 weeks</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Symbicort Turbuhaler</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Formoterol (Oxis Turbuhaler)</intervention_name>
    <description>2 X 4.5 microgram, inhalation, twice daily, 12 weeks</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Oxis Turbuhaler</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A current clinical diagnosis of Chronic Obstructive Pulmonary Disease

          -  Documented Chronic Obstructive Pulmonary Disease symptoms for more than 2 years

          -  A smoking history of at least 10 pack years

        Exclusion Criteria:

          -  History and/or current clinical diagnosis of asthma

          -  History and/or current clinical diagnosis of atopic diseases such as allergic rhinitis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lars-Göran Carlsson, MD</last_name>
    <role>Study Chair</role>
    <affiliation>AstraZeneca R&amp;D, Lund, Sweden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yoshinosuke Fukuchi, M.D., PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Respiratory medicine, Juntendo University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mysore</city>
        <state>Karnataka</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Trivandrum</city>
        <state>Kerala</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Indore</city>
        <state>Madhya Pradesh</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nagpur</city>
        <state>Maharashtra</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Coimbatore</city>
        <state>Tamil Nadu</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Okazaki</city>
        <state>Aichi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seto</city>
        <state>Aichi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toyota-shi</city>
        <state>Aichi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toyota</city>
        <state>Aichi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Akita-shi</city>
        <state>Akita</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yanagawa</city>
        <state>Fukuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Takayama-shi</city>
        <state>Gifu</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Maebashi</city>
        <state>Gunma</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>OTA</city>
        <state>Gunma</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hiroshima-shi</city>
        <state>Hiroshima</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Asahikawa</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Obihiro</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tomakomai</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Himeji</city>
        <state>Hyogo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Itami</city>
        <state>Hyogo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kobe</city>
        <state>Hyogo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Naka-gun</city>
        <state>Ibaragi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hitachi</city>
        <state>Ibaraki</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tsukuba</city>
        <state>Ibaraki</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kanazawa</city>
        <state>Ishikawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sakaide</city>
        <state>Kagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kagoshima-shi</city>
        <state>Kagoshima</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fujisawa</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kawasaki-shi</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yokohama-shi</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zama-shi</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Matsusaka-shi</city>
        <state>MIE</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sendai</city>
        <state>Miyagi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shibata</city>
        <state>Miyagi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chino-shi</city>
        <state>Nagano</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Matsumoto</city>
        <state>Nagano</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Isahaya-shi</city>
        <state>Nagasaki</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nagaoka</city>
        <state>Niigata</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saiki-shi</city>
        <state>Oita</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yufu-shi</city>
        <state>Oita</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kurashiki-shi</city>
        <state>Okayama</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Okayama-shi</city>
        <state>Okayama</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Urasoe-shi</city>
        <state>Okinawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Izumi-shi</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kishiwada</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moriguchi</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Osaka-shi</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Researche Site</name>
      <address>
        <city>Sakai-shi</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kitakatsushika-gun</city>
        <state>Saitama</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Koshigaya-shi</city>
        <state>Saitama</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Matsue</city>
        <state>Shimane</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chuo</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Itabashi-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Meguro</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Minato-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Setagaya</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shinagawa-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Suginami-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sumida-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gifu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kochi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kyoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saga</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wakayama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ansan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Researche Site</name>
      <address>
        <city>San Fernando</city>
        <state>Pampanga</state>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Davao City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Iloilo City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lipa City, Batangas</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Olongapo City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Quezon City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bialystok</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bydgoszcz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chodziez</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jaroslaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Karpacz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lodz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Loma</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ostrow Wielkopolski</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pila</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Poznan</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ruda Slaska</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Slupca</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tczew</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Torun</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Turek</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wloszczowa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zabrze</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zawadzkie</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Znin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barnaul</city>
        <state>Russia</state>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ekaterinburg</city>
        <state>Russia</state>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kazan</city>
        <state>Russia</state>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <state>Russia</state>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>St.petersburg</city>
        <state>Russia</state>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Novosibirsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vladikavkaz</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chiayi</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Keelung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dnipropetrovsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Donetsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kyiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Poltava</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Uzhgorod</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vinytsa</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zaporozye</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hanoi</city>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ho Chi Minh</city>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Philippines</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Taiwan</country>
    <country>Ukraine</country>
    <country>Vietnam</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 11, 2010</study_first_submitted>
  <study_first_submitted_qc>February 16, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 17, 2010</study_first_posted>
  <results_first_submitted>March 21, 2012</results_first_submitted>
  <results_first_submitted_qc>September 25, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 25, 2012</results_first_posted>
  <last_update_submitted>September 25, 2012</last_update_submitted>
  <last_update_submitted_qc>September 25, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 25, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Symbicort</keyword>
  <keyword>Oxis</keyword>
  <keyword>Chronic Obstructive Pulmonary Disease</keyword>
  <keyword>COPD</keyword>
  <keyword>Efficacy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Formoterol Fumarate</mesh_term>
    <mesh_term>Budesonide</mesh_term>
    <mesh_term>Budesonide, Formoterol Fumarate Drug Combination</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The first participant entered the study on 28 January 2010, and the last participant completed the study on 30 March 2011. A total of 1,710 participants were enrolled at 163 centres in 9 countries in Asia and Europe, and 1,293 participants who fulfilled the randomisation criteria were randomised.</recruitment_details>
      <pre_assignment_details>The study started with an enrolment visit, Visit 1, 0 to 4 weeks prior to Visit 2, and 1-2 week run-in period before randomization. At Visit 2 participants had to have pre-bronchodilatory forced expiratory volume in one second (FEV1) less than or equal to 50 percent of the predicted normal value.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Symbicort Turbuhaler (Experimental)</title>
          <description>Symbicort Turbuhaler 160/4.5 microgram (mcg), 2 inhalations twice daily (bid)</description>
        </group>
        <group group_id="P2">
          <title>Oxis Turbuhaler (Active Comparator)</title>
          <description>Oxis Turbuhaler 4.5 microgram (mcg), 2 inhalations twice daily(bid)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="636"/>
                <participants group_id="P2" count="657"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="594"/>
                <participants group_id="P2" count="601"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="56"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Eligibility criteria not fulfilled</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Severe non-compliance to protocol</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Due to deteriorating health condition</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Symbicort Turbuhaler (Experimental)</title>
          <description>Symbicort Turbuhaler 160/4.5 microgram (mcg), 2 inhalations twice daily (bid)</description>
        </group>
        <group group_id="B2">
          <title>Oxis Turbuhaler (Active Comparator)</title>
          <description>Oxis Turbuhaler 4.5 microgram (mcg), 2 inhalations twice daily(bid)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="636"/>
            <count group_id="B2" value="657"/>
            <count group_id="B3" value="1293"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.5" lower_limit="40" upper_limit="89"/>
                    <measurement group_id="B2" value="65.6" lower_limit="40" upper_limit="87"/>
                    <measurement group_id="B3" value="65.1" lower_limit="40" upper_limit="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79"/>
                    <measurement group_id="B2" value="64"/>
                    <measurement group_id="B3" value="143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="557"/>
                    <measurement group_id="B2" value="593"/>
                    <measurement group_id="B3" value="1150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pre-dose Forced Expiratory Volume in One Second (FEV1)</title>
        <description>The ratio, expressed as percentage, of the geometric mean of available data for Weeks 0, 4, 8 and 12 to the baseline for each treatment group</description>
        <time_frame>Before randomization, 0, 4, 8 and 12 weeks after randomization</time_frame>
        <population>The analysis set for efficacy was based on the Full Analysis Set (FAS). Available data represent patients who had both baseline and on treatment data which is required to be included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Symbicort Turbuhaler (Experimental)</title>
            <description>Symbicort Turbuhaler 160/4.5 microgram (mcg), 2 inhalations twice daily (bid)</description>
          </group>
          <group group_id="O2">
            <title>Oxis Turbuhaler (Active Comparator)</title>
            <description>Oxis Turbuhaler 4.5 microgram (mcg), 2 inhalations twice daily(bid)</description>
          </group>
        </group_list>
        <measure>
          <title>Pre-dose Forced Expiratory Volume in One Second (FEV1)</title>
          <description>The ratio, expressed as percentage, of the geometric mean of available data for Weeks 0, 4, 8 and 12 to the baseline for each treatment group</description>
          <population>The analysis set for efficacy was based on the Full Analysis Set (FAS). Available data represent patients who had both baseline and on treatment data which is required to be included in the analysis.</population>
          <units>percentage of Baseline</units>
          <param>Geometric Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="618"/>
                <count group_id="O2" value="635"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104.6" lower_limit="37.4" upper_limit="311.1"/>
                    <measurement group_id="O2" value="101.5" lower_limit="35.1" upper_limit="218.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>1 Hour Post Dose Forced Expiratory Volume in One Second (FEV1)</title>
        <description>The ratio, expressed as percentage, of the geometric mean of available data for Weeks 0, 4, 8 and 12 to the baseline for each treatment group</description>
        <time_frame>Before randomization, 0, 4, 8 and 12 weeks after randomization</time_frame>
        <population>The analysis set for efficacy was based on the Full Analysis Set (FAS). Available data represent patients who had both baseline and on treatment data which is required to be included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Symbicort Turbuhaler (Experimental)</title>
            <description>Symbicort Turbuhaler 160/4.5 microgram (mcg), 2 inhalations twice daily (bid)</description>
          </group>
          <group group_id="O2">
            <title>Oxis Turbuhaler (Active Comparator)</title>
            <description>Oxis Turbuhaler 4.5 microgram (mcg), 2 inhalations twice daily(bid)</description>
          </group>
        </group_list>
        <measure>
          <title>1 Hour Post Dose Forced Expiratory Volume in One Second (FEV1)</title>
          <description>The ratio, expressed as percentage, of the geometric mean of available data for Weeks 0, 4, 8 and 12 to the baseline for each treatment group</description>
          <population>The analysis set for efficacy was based on the Full Analysis Set (FAS). Available data represent patients who had both baseline and on treatment data which is required to be included in the analysis.</population>
          <units>percentage of Baseline</units>
          <param>Geometric Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="635"/>
                <count group_id="O2" value="657"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113.9" lower_limit="55.5" upper_limit="336.3"/>
                    <measurement group_id="O2" value="111.2" lower_limit="51.3" upper_limit="203.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pre-dose Forced Vital Capacity (FVC)</title>
        <description>The ratio, expressed as percentage, of the geometric mean of available data for Weeks 0, 4, 8 and 12 to the baseline for each treatment group</description>
        <time_frame>Before randomization, 0, 4, 8 and 12 weeks after randomization</time_frame>
        <population>The analysis set for efficacy was based on the Full Analysis Set (FAS). Available data represent patients who had both baseline and on treatment data which is required to be included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Symbicort Turbuhaler (Experimental)</title>
            <description>Symbicort Turbuhaler 160/4.5 microgram (mcg), 2 inhalations twice daily (bid)</description>
          </group>
          <group group_id="O2">
            <title>Oxis Turbuhaler (Active Comparator)</title>
            <description>Oxis Turbuhaler 4.5 microgram (mcg), 2 inhalations twice daily(bid)</description>
          </group>
        </group_list>
        <measure>
          <title>Pre-dose Forced Vital Capacity (FVC)</title>
          <description>The ratio, expressed as percentage, of the geometric mean of available data for Weeks 0, 4, 8 and 12 to the baseline for each treatment group</description>
          <population>The analysis set for efficacy was based on the Full Analysis Set (FAS). Available data represent patients who had both baseline and on treatment data which is required to be included in the analysis.</population>
          <units>percentage of Baseline</units>
          <param>Geometric Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="618"/>
                <count group_id="O2" value="635"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102.2" lower_limit="57.3" upper_limit="313.8"/>
                    <measurement group_id="O2" value="100.9" lower_limit="61.5" upper_limit="347.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>1 Hour Post-dose Forced Vital Capacity (FVC)</title>
        <description>The ratio, expressed as percentage, of the geometric mean of available data for Weeks 0, 4, 8 and 12 to the baseline for each treatment group</description>
        <time_frame>Before randomization, 0, 4, 8 and 12 weeks after randomization</time_frame>
        <population>The analysis set for efficacy was based on the Full Analysis Set (FAS. Available data represent patients who had both baseline and on treatment data which is required to be included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Symbicort Turbuhaler (Experimental)</title>
            <description>Symbicort Turbuhaler 160/4.5 microgram (mcg), 2 inhalations twice daily (bid)</description>
          </group>
          <group group_id="O2">
            <title>Oxis Turbuhaler (Active Comparator)</title>
            <description>Oxis Turbuhaler 4.5 microgram (mcg), 2 inhalations twice daily(bid)</description>
          </group>
        </group_list>
        <measure>
          <title>1 Hour Post-dose Forced Vital Capacity (FVC)</title>
          <description>The ratio, expressed as percentage, of the geometric mean of available data for Weeks 0, 4, 8 and 12 to the baseline for each treatment group</description>
          <population>The analysis set for efficacy was based on the Full Analysis Set (FAS. Available data represent patients who had both baseline and on treatment data which is required to be included in the analysis.</population>
          <units>percentage of Baseline</units>
          <param>Geometric Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="635"/>
                <count group_id="O2" value="657"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110.1" lower_limit="62.0" upper_limit="262.7"/>
                    <measurement group_id="O2" value="108.7" lower_limit="63.5" upper_limit="272.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Exacerbations</title>
        <description>A Chronic Obstructive Pulmonary Disease (COPD) exacerbation was defined as worsening in COPD symptoms requiring treatment with either a course of systemic steroid or hospitalisation. The percentage of participants who had experienced COPD exacerbation at the end of the study for each treatment group.</description>
        <time_frame>Daily during 12-week randomization treatment</time_frame>
        <population>The analysis set for efficacy was based on the Full Analysis Set (FAS).Available data represent patients who had both baseline and on treatment data which is required to be included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Symbicort Turbuhaler (Experimental)</title>
            <description>Symbicort Turbuhaler 160/4.5 microgram (mcg), 2 inhalations twice daily (bid)</description>
          </group>
          <group group_id="O2">
            <title>Oxis Turbuhaler (Active Comparator)</title>
            <description>Oxis Turbuhaler 4.5 microgram (mcg), 2 inhalations twice daily(bid)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Exacerbations</title>
          <description>A Chronic Obstructive Pulmonary Disease (COPD) exacerbation was defined as worsening in COPD symptoms requiring treatment with either a course of systemic steroid or hospitalisation. The percentage of participants who had experienced COPD exacerbation at the end of the study for each treatment group.</description>
          <population>The analysis set for efficacy was based on the Full Analysis Set (FAS).Available data represent patients who had both baseline and on treatment data which is required to be included in the analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="636"/>
                <count group_id="O2" value="657"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.9"/>
                    <measurement group_id="O2" value="16.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Chronic Obstructive Pulmonary Disease (COPD) Exacerbation</title>
        <description>A Chronic Obstructive Pulmonary Disease (COPD) exacerbation was defined as worsening in COPD symptoms requiring treatment with either a course of systemic steroid or hospitalisation. Number of COPD exacerbation during 12-week randomization treatment</description>
        <time_frame>Daily during 12-week randomization treatment</time_frame>
        <population>The analysis set for efficacy was based on the Full Analysis Set (FAS). Available data represent patients who had both baseline and on treatment data which is required to be included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Symbicort Turbuhaler (Experimental)</title>
            <description>Symbicort Turbuhaler 160/4.5 microgram (mcg), 2 inhalations twice daily (bid)</description>
          </group>
          <group group_id="O2">
            <title>Oxis Turbuhaler (Active Comparator)</title>
            <description>Oxis Turbuhaler 4.5 microgram (mcg), 2 inhalations twice daily(bid)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Chronic Obstructive Pulmonary Disease (COPD) Exacerbation</title>
          <description>A Chronic Obstructive Pulmonary Disease (COPD) exacerbation was defined as worsening in COPD symptoms requiring treatment with either a course of systemic steroid or hospitalisation. Number of COPD exacerbation during 12-week randomization treatment</description>
          <population>The analysis set for efficacy was based on the Full Analysis Set (FAS). Available data represent patients who had both baseline and on treatment data which is required to be included in the analysis.</population>
          <units>event</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="636"/>
                <count group_id="O2" value="657"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93"/>
                    <measurement group_id="O2" value="151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Morning Peak Expiratory Flow(PEF)</title>
        <description>The change from Run-in period average to Treatment period average for each treatment group</description>
        <time_frame>Daily during run-in period and daily during 12-week randomization treatment</time_frame>
        <population>The analysis set for efficacy was based on the Full Analysis Set (FAS). Available data represent patients who had both baseline and on treatment data which is required to be included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Symbicort Turbuhaler (Experimental)</title>
            <description>Symbicort Turbuhaler 160/4.5 microgram (mcg), 2 inhalations twice daily (bid)</description>
          </group>
          <group group_id="O2">
            <title>Oxis Turbuhaler (Active Comparator)</title>
            <description>Oxis Turbuhaler 4.5 microgram (mcg), 2 inhalations twice daily(bid)</description>
          </group>
        </group_list>
        <measure>
          <title>Morning Peak Expiratory Flow(PEF)</title>
          <description>The change from Run-in period average to Treatment period average for each treatment group</description>
          <population>The analysis set for efficacy was based on the Full Analysis Set (FAS). Available data represent patients who had both baseline and on treatment data which is required to be included in the analysis.</population>
          <units>Liter/minute (L/min)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="613"/>
                <count group_id="O2" value="637"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.29" spread="36.58"/>
                    <measurement group_id="O2" value="-4.78" spread="30.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evening Peak Expiratory Flow (PEF)</title>
        <description>The change from Run-in period average to Treatment period average for each treatment group</description>
        <time_frame>Daily during run-in period and daily during 12-week randomization treatment</time_frame>
        <population>The analysis set for efficacy was based on the Full Analysis Set (FAS). Available data represent patients who had both baseline and on treatment data which is required to be included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Symbicort Turbuhaler (Experimental)</title>
            <description>Symbicort Turbuhaler 160/4.5 microgram (mcg), 2 inhalations twice daily (bid)</description>
          </group>
          <group group_id="O2">
            <title>Oxis Turbuhaler (Active Comparator)</title>
            <description>Oxis Turbuhaler 4.5 microgram (mcg), 2 inhalations twice daily(bid)</description>
          </group>
        </group_list>
        <measure>
          <title>Evening Peak Expiratory Flow (PEF)</title>
          <description>The change from Run-in period average to Treatment period average for each treatment group</description>
          <population>The analysis set for efficacy was based on the Full Analysis Set (FAS). Available data represent patients who had both baseline and on treatment data which is required to be included in the analysis.</population>
          <units>Liter/minute (L/min)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="612"/>
                <count group_id="O2" value="637"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.55" spread="36.57"/>
                    <measurement group_id="O2" value="-5.13" spread="31.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Number of Day With Exacerbation</title>
        <description>Total number of days with COPD exacerbation for each treatment group</description>
        <time_frame>Daily during 12-week randomization treatment</time_frame>
        <population>The analysis set for efficacy was based on the Full Analysis Set (FAS). Available data represent patients who had both baseline and on treatment data which is required to be included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Symbicort Turbuhaler (Experimental)</title>
            <description>Symbicort Turbuhaler 160/4.5 microgram (mcg), 2 inhalations twice daily (bid)</description>
          </group>
          <group group_id="O2">
            <title>Oxis Turbuhaler (Active Comparator)</title>
            <description>Oxis Turbuhaler 4.5 microgram (mcg), 2 inhalations twice daily(bid)</description>
          </group>
        </group_list>
        <measure>
          <title>Total Number of Day With Exacerbation</title>
          <description>Total number of days with COPD exacerbation for each treatment group</description>
          <population>The analysis set for efficacy was based on the Full Analysis Set (FAS). Available data represent patients who had both baseline and on treatment data which is required to be included in the analysis.</population>
          <units>days</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="636"/>
                <count group_id="O2" value="657"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="653"/>
                    <measurement group_id="O2" value="1098"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Morning Forced Expiratory Volume in One Second (FEV1)</title>
        <description>The change from Run-in period average to Treatment period average for each treatment group</description>
        <time_frame>Daily during run-in period and daily during 12-week randomization treatment</time_frame>
        <population>The analysis set for efficacy was based on the Full Analysis Set (FAS). Available data represent patients who had both baseline and on treatment data which is required to be included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Symbicort Turbuhaler (Experimental)</title>
            <description>Symbicort Turbuhaler 160/4.5 microgram (mcg), 2 inhalations twice daily (bid)</description>
          </group>
          <group group_id="O2">
            <title>Oxis Turbuhaler (Active Comparator)</title>
            <description>Oxis Turbuhaler 4.5 microgram (mcg), 2 inhalations twice daily(bid)</description>
          </group>
        </group_list>
        <measure>
          <title>Morning Forced Expiratory Volume in One Second (FEV1)</title>
          <description>The change from Run-in period average to Treatment period average for each treatment group</description>
          <population>The analysis set for efficacy was based on the Full Analysis Set (FAS). Available data represent patients who had both baseline and on treatment data which is required to be included in the analysis.</population>
          <units>Liter (L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="613"/>
                <count group_id="O2" value="637"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0244" spread="0.2136"/>
                    <measurement group_id="O2" value="-0.0312" spread="0.1712"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evening Forced Expiratory Volume in One Second (FEV1)</title>
        <description>The change from Run-in period average to Treatment period average for each treatment group</description>
        <time_frame>Daily during run-in period and daily during 12-week randomization treatment</time_frame>
        <population>The analysis set for efficacy was based on the Full Analysis Set (FAS). Available data represent patients who had both baseline and on treatment data which is required to be included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Symbicort Turbuhaler (Experimental)</title>
            <description>Symbicort Turbuhaler 160/4.5 microgram (mcg), 2 inhalations twice daily (bid)</description>
          </group>
          <group group_id="O2">
            <title>Oxis Turbuhaler (Active Comparator)</title>
            <description>Oxis Turbuhaler 4.5 microgram (mcg), 2 inhalations twice daily(bid)</description>
          </group>
        </group_list>
        <measure>
          <title>Evening Forced Expiratory Volume in One Second (FEV1)</title>
          <description>The change from Run-in period average to Treatment period average for each treatment group</description>
          <population>The analysis set for efficacy was based on the Full Analysis Set (FAS). Available data represent patients who had both baseline and on treatment data which is required to be included in the analysis.</population>
          <units>Liter (L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="612"/>
                <count group_id="O2" value="637"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0176" spread="0.2268"/>
                    <measurement group_id="O2" value="-0.0324" spread="0.1724"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Night-time Awakening Due to Chronic Obstructive Pulmonary Disease (COPD) Symptoms</title>
        <description>Scored 0 to 1 (0 = no awakening and 1 = awakening). The change from Run-in period average to Treatment period average for each treatment group</description>
        <time_frame>Daily during run-in period and daily during 12-week randomization treatment</time_frame>
        <population>The analysis set for efficacy was based on the Full Analysis Set (FAS). Available data represent patients who had both baseline and on treatment data which is required to be included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Symbicort Turbuhaler (Experimental)</title>
            <description>Symbicort Turbuhaler 160/4.5 microgram (mcg), 2 inhalations twice daily (bid)</description>
          </group>
          <group group_id="O2">
            <title>Oxis Turbuhaler (Active Comparator)</title>
            <description>Oxis Turbuhaler 4.5 microgram (mcg), 2 inhalations twice daily(bid)</description>
          </group>
        </group_list>
        <measure>
          <title>Night-time Awakening Due to Chronic Obstructive Pulmonary Disease (COPD) Symptoms</title>
          <description>Scored 0 to 1 (0 = no awakening and 1 = awakening). The change from Run-in period average to Treatment period average for each treatment group</description>
          <population>The analysis set for efficacy was based on the Full Analysis Set (FAS). Available data represent patients who had both baseline and on treatment data which is required to be included in the analysis.</population>
          <units>Nights with symptoms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="628"/>
                <count group_id="O2" value="647"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.20" spread="0.67"/>
                    <measurement group_id="O2" value="-0.15" spread="0.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Breathlessness Due to Chronic Obstructive Pulmonary Disease (COPD) Symptoms</title>
        <description>There are 5 alternatives (scored 0 to 4, with 4 being the most severe condition). The change from Run-in period average to Treatment period average for each treatment group</description>
        <time_frame>Daily during run-in period and daily during 12-week randomization treatment</time_frame>
        <population>The analysis set for efficacy was based on the Full Analysis Set (FAS). Available data represent patients who had both baseline and on treatment data which is required to be included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Symbicort Turbuhaler (Experimental)</title>
            <description>Symbicort Turbuhaler 160/4.5 microgram (mcg), 2 inhalations twice daily (bid)</description>
          </group>
          <group group_id="O2">
            <title>Oxis Turbuhaler (Active Comparator)</title>
            <description>Oxis Turbuhaler 4.5 microgram (mcg), 2 inhalations twice daily(bid)</description>
          </group>
        </group_list>
        <measure>
          <title>Breathlessness Due to Chronic Obstructive Pulmonary Disease (COPD) Symptoms</title>
          <description>There are 5 alternatives (scored 0 to 4, with 4 being the most severe condition). The change from Run-in period average to Treatment period average for each treatment group</description>
          <population>The analysis set for efficacy was based on the Full Analysis Set (FAS). Available data represent patients who had both baseline and on treatment data which is required to be included in the analysis.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="628"/>
                <count group_id="O2" value="647"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.34" spread="0.66"/>
                    <measurement group_id="O2" value="-0.23" spread="0.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cough Due to Chronic Obstructive Pulmonary Disease (COPD) Symptoms</title>
        <description>There are 5 alternatives (scored 0 to 4, with 4 being the most severe condition). The change from Run-in period average to Treatment period average for each treatment group</description>
        <time_frame>Daily during run-in period and daily during 12-week randomization treatment</time_frame>
        <population>The analysis set for efficacy was based on the Full Analysis Set (FAS). Available data represent patients who had both baseline and on treatment data which is required to be included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Symbicort Turbuhaler (Experimental)</title>
            <description>Symbicort Turbuhaler 160/4.5 microgram (mcg), 2 inhalations twice daily (bid)</description>
          </group>
          <group group_id="O2">
            <title>Oxis Turbuhaler (Active Comparator)</title>
            <description>Oxis Turbuhaler 4.5 microgram (mcg), 2 inhalations twice daily(bid)</description>
          </group>
        </group_list>
        <measure>
          <title>Cough Due to Chronic Obstructive Pulmonary Disease (COPD) Symptoms</title>
          <description>There are 5 alternatives (scored 0 to 4, with 4 being the most severe condition). The change from Run-in period average to Treatment period average for each treatment group</description>
          <population>The analysis set for efficacy was based on the Full Analysis Set (FAS). Available data represent patients who had both baseline and on treatment data which is required to be included in the analysis.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="628"/>
                <count group_id="O2" value="647"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.24" spread="0.70"/>
                    <measurement group_id="O2" value="-0.24" spread="0.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Chronic Obstructive Pulmonary Disease (COPD) Symptom Score</title>
        <description>The Total COPD Symptom score is the sum of the measures night-time awakening, breathlessness and cough, ranges from 0 to 12 with 12 being the most severe. The change from Run-in period average to Treatment period average for each treatment group.</description>
        <time_frame>Daily during run-in period and daily during 12-week randomization treatment</time_frame>
        <population>The analysis set for efficacy was based on the Full Analysis Set (FAS). Available data represent patients who had both baseline and on treatment data which is required to be included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Symbicort Turbuhaler (Experimental)</title>
            <description>Symbicort Turbuhaler 160/4.5 microgram (mcg), 2 inhalations twice daily (bid)</description>
          </group>
          <group group_id="O2">
            <title>Oxis Turbuhaler (Active Comparator)</title>
            <description>Oxis Turbuhaler 4.5 microgram (mcg), 2 inhalations twice daily(bid)</description>
          </group>
        </group_list>
        <measure>
          <title>Total Chronic Obstructive Pulmonary Disease (COPD) Symptom Score</title>
          <description>The Total COPD Symptom score is the sum of the measures night-time awakening, breathlessness and cough, ranges from 0 to 12 with 12 being the most severe. The change from Run-in period average to Treatment period average for each treatment group.</description>
          <population>The analysis set for efficacy was based on the Full Analysis Set (FAS). Available data represent patients who had both baseline and on treatment data which is required to be included in the analysis.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="628"/>
                <count group_id="O2" value="647"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.78" spread="1.62"/>
                    <measurement group_id="O2" value="-0.61" spread="1.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Use of Rescue Medication</title>
        <description>The change from Run-in period average to Treatment period average for each treatment group.</description>
        <time_frame>Daily during run-in period and daily during 12-week randomization treatment</time_frame>
        <population>The analysis set for efficacy was based on the Full Analysis Set (FAS). Available data represent patients who had both baseline and on treatment data which is required to be included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Symbicort Turbuhaler (Experimental)</title>
            <description>Symbicort Turbuhaler 160/4.5 microgram (mcg), 2 inhalations twice daily (bid)</description>
          </group>
          <group group_id="O2">
            <title>Oxis Turbuhaler (Active Comparator)</title>
            <description>Oxis Turbuhaler 4.5 microgram (mcg), 2 inhalations twice daily(bid)</description>
          </group>
        </group_list>
        <measure>
          <title>Use of Rescue Medication</title>
          <description>The change from Run-in period average to Treatment period average for each treatment group.</description>
          <population>The analysis set for efficacy was based on the Full Analysis Set (FAS). Available data represent patients who had both baseline and on treatment data which is required to be included in the analysis.</population>
          <units>inhalations/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="628"/>
                <count group_id="O2" value="647"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.51" spread="1.51"/>
                    <measurement group_id="O2" value="-0.26" spread="1.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>St George’s Respiratory Questionnaire (SGRQ) Total Score</title>
        <description>The change from Run-in period average to Treatment period average for each treatment group. The SGRQ ranges from 0 (no impairment of quality of life) to 100 (highest impairment of quality of life).</description>
        <time_frame>Daily during run-in period and daily during 12-week randomization treatment</time_frame>
        <population>The analysis set for efficacy was based on the Full Analysis Set (FAS). Available data represent patients who had both baseline and on treatment data which is required to be included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Symbicort Turbuhaler (Experimental)</title>
            <description>Symbicort Turbuhaler 160/4.5 microgram (mcg), 2 inhalations twice daily (bid)</description>
          </group>
          <group group_id="O2">
            <title>Oxis Turbuhaler (Active Comparator)</title>
            <description>Oxis Turbuhaler 4.5 microgram (mcg), 2 inhalations twice daily(bid)</description>
          </group>
        </group_list>
        <measure>
          <title>St George’s Respiratory Questionnaire (SGRQ) Total Score</title>
          <description>The change from Run-in period average to Treatment period average for each treatment group. The SGRQ ranges from 0 (no impairment of quality of life) to 100 (highest impairment of quality of life).</description>
          <population>The analysis set for efficacy was based on the Full Analysis Set (FAS). Available data represent patients who had both baseline and on treatment data which is required to be included in the analysis.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="621"/>
                <count group_id="O2" value="634"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.37" spread="14.544"/>
                    <measurement group_id="O2" value="-2.90" spread="13.783"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Symbicort Turbuhaler (Experimental)</title>
          <description>Symbicort Turbuhaler 160/4.5 microgram (mcg), 2 inhalations twice daily (bid)</description>
        </group>
        <group group_id="E2">
          <title>Oxis Turbuhaler (Active Comparator)</title>
          <description>Oxis Turbuhaler 4.5 microgram (mcg), 2 inhalations twice daily(bid)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="636"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="657"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="636"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="657"/>
              </event>
              <event>
                <sub_title>ANGINA PECTORIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="636"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="657"/>
              </event>
              <event>
                <sub_title>ANGINA UNSTABLE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="636"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="657"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="636"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="657"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE CHRONIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="636"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="657"/>
              </event>
              <event>
                <sub_title>CARDIOVASCULAR INSUFFICIENCY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="636"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="657"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY INSUFFICIENCY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="636"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="657"/>
              </event>
              <event>
                <sub_title>MYOCARDIAL ISCHAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="636"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="657"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>AMAUROSIS FUGAX</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="636"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="657"/>
              </event>
              <event>
                <sub_title>CATARACT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="636"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="657"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="636"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="657"/>
              </event>
              <event>
                <sub_title>COLITIS ISCHAEMIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="636"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="657"/>
              </event>
              <event>
                <sub_title>DIVERTICULUM INTESTINAL HAEMORRHAGIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="636"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="657"/>
              </event>
              <event>
                <sub_title>ILEUS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="636"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="657"/>
              </event>
              <event>
                <sub_title>PANCREATIC MASS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="636"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="657"/>
              </event>
              <event>
                <sub_title>PERITONITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="636"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="657"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>DEATH</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="636"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="657"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>CHOLECYSTITIS ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="636"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="657"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>APPENDICITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="636"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="657"/>
              </event>
              <event>
                <sub_title>PNEUMONIA BACTERIAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="636"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="657"/>
              </event>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="636"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="657"/>
              </event>
              <event>
                <sub_title>BRONCHOPNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="636"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="657"/>
              </event>
              <event>
                <sub_title>POSTOPERATIVE ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="636"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="657"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>COMPUTERISED TOMOGRAM THORAX ABNORMAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="636"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="657"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>HYPOGLYCAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="636"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="657"/>
              </event>
              <event>
                <sub_title>HYPOKALAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="636"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="657"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>COLON CANCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="636"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="657"/>
              </event>
              <event>
                <sub_title>GASTRIC CANCER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="636"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="657"/>
              </event>
              <event>
                <sub_title>HEPATIC NEOPLASM MALIGNANT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="636"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="657"/>
              </event>
              <event>
                <sub_title>LUNG NEOPLASM MALIGNANT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="636"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="657"/>
              </event>
              <event>
                <sub_title>METASTASES TO LUNG</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="636"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="657"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>BRAIN STEM STROKE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="636"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="657"/>
              </event>
              <event>
                <sub_title>HYPOXIC-ISCHAEMIC ENCEPHALOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="636"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="657"/>
              </event>
              <event>
                <sub_title>ISCHAEMIC STROKE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="636"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="657"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>CHRONIC OBSTRUCTIVE PULMONARY DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="636"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="657"/>
              </event>
              <event>
                <sub_title>PNEUMOTHORAX</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="636"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="657"/>
              </event>
              <event>
                <sub_title>ACUTE RESPIRATORY FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="636"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="657"/>
              </event>
              <event>
                <sub_title>HAEMOPTYSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="636"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="657"/>
              </event>
              <event>
                <sub_title>INFECTIVE EXACERBATION OF CHRONIC OBSTRUCTIVE AIRWAYS DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="636"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="657"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="636"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="657"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>AORTIC ANEURYSM RUPTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="636"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="657"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="636"/>
                <counts group_id="E2" subjects_affected="66" subjects_at_risk="657"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="636"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="657"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic Obstructive Pulmonary Disease</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="636"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="657"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gerard Lynch</name_or_title>
      <organization>AstraZeneca</organization>
      <email>aztrial_results_posting@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

